|
Mutation Information
|
Mutation Site
|
V82A |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
PR |
|
Relevant Drug
|
bictegravir (BIC);emtricitabine (FTC);tenofovir alafenamide |
|
Country
|
Australia;Europe;North America |
Literature Information
|
PubMed PMID
|
31430369
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2019 |
|
Journal
|
The Journal of antimicrobial chemotherapy |
|
Title
|
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. |
|
Author
|
Andreatta K,Willkom M,Martin R,Chang S,Wei L,Liu H,Liu YP,Graham H,Quirk E,Martin H,White KL |
|
Evidence
|
Primary PI-R substitutions observed were: M46I/L (n=22), L90M (n=13), D30N (n=9), V82A/L/T (n=7), I84V (n=5), I47V, N83D and N88S (n=2 each), and V32I, I50V, I54L, Q58E and L76V (n=1 each).
|
|
|
HIV Mutation Detail Information